Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bivalirudin versus unfractionated heparin in transfemoral TAVR
2012-000632-26Phase 3Completed
- Sponsor
- The Medicines Company
- Start
- May 2012
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3 trial of bivalirudin and heparin in aortic valve disease (AVD) (2 arms), sponsored by The Medicines Company. Primary endpoints: Major bleeding and Net adverse cardiac events. Started May 2012; status: completed.
02
Drugs
bivalirudinheparin
03
Conditions
aortic valve disease (AVD)
Beyond the preview
Go deeper on 2012-000632-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000632-26.